Insulet Corporation (PODD) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · United States · ISIN US45784P1012

Price

148.12 USD

Market cap

10.27 bn USD

P/E (2026)

–

P/S (2026)

–

Dividend yield

0.00 %

Net margin

–

Return on equity (ROE)

–

Return on assets (ROA)

–

Insulet Corporation financials

Fiscal year	2025
Revenue	2.71 bn USD
Gross profit	1.94 bn USD
Operating income	473.80 m USD
EBIT	364.20 m USD
Net income	247.10 m USD
Diluted EPS – continuing operations	3.48 USD

Full history since 2002, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.